Condition: Alpha 1 Antitrypsin Deficiency · Sponsor: Grifols Therapeutics LLC
This study is designed to compare two different weekly doses of a medicine called Alpha1-Proteinase Inhibitor given by injection under the skin with the standard doses of the same medicine given through a vein. Adults with Alpha-1 Antitrypsin Deficiency will take part. Participants will be randomly assigned to one of the treatment groups, and both the study doctors and participants will know which treatment is being given. The main goals of the study are to understand how the body processes the medicine (pharmacokinetics) and to assess how safe and well tolerated the different weekly doses are.
This description comes directly from the study's public registry record.
Beatriz Garcia Castro · +(34) 670923669 · beatriz.garcia@grifols.com
Lydia Martinez Garrido · +(34) 670929415 · lydia.martinez@grifols.com
Always discuss trial participation with your own doctor first.
| GC2501 Study Site 106 | Birmingham, Alabama, United States | Not Yet Recruiting |
| GC2501 Study Site 102 | Phoenix, Arizona, United States | Not Yet Recruiting |
| GC2501 Study Site 107 | Scottsdale, Arizona, United States | Not Yet Recruiting |
| GC2501 Study Site 100 | Los Angelas, California, United States | Not Yet Recruiting |
| GC2501 Study Site 103 | Gainesville, Florida, United States | Not Yet Recruiting |
| GC2501 Study Site 105 | Miami, Florida, United States | Not Yet Recruiting |
| GC2501 Study Site 108 | Rochester, Minnesota, United States | Not Yet Recruiting |
| GC2501 Study Site 104 | Cleveland, Ohio, United States | Not Yet Recruiting |
| GC2501 Study Site 101 | Charleston, South Carolina, United States | Not Yet Recruiting |
| GC2501 Study Site 109 | Dallas, Texas, United States | Not Yet Recruiting |
| GC2501 Study Site 150 | Vejle, Denmark | Recruiting |
| GC2501 Study Site 250 | Freiburg im Breisgau, Germany | Not Yet Recruiting |
+ 10 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07555483